Real-time quantitative PCR analysis of celecoxib treatment on OC tissue chip

To test the utility of iPSC-derived OC tissue chip in drug screening, Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor commonly used to treat OA, was administered to the system. Celecoxib was administered at 10 µM concentration, and showed no noticeable adverse effect on the health of normal chondral tissue. Administration of Celecoxib to both OC-C and OC-B were used to simulate the typically systemic action of Celecoxib, represented by the “SY” group. In addition, we also examined the potential effect of intraarticular (IA) application of Celecoxib in treating OA, by delivery only to OC-C, namely the “IA” group. Normal OC tissues without any treatments served as the control (CL). qPCR gene expression profiling: catabolic, inflammatory and chondrogenic gene expression of CL, OA, SY and IA were compared. Total RNA from each sample was used for gene expression analysis and normalized to RPL13A.